Your browser doesn't support javascript.
loading
Factors associated with treatment success and death in cases with multidrug-resistant tuberculosis in Bulgaria, 2009-2010.
Milanov, Vladimir; Falzon, Dennis; Zamfirova, Mariya; Varleva, Tonka; Bachiyska, Elizabeta; Koleva, Antoniya; Dara, Masoud.
Afiliação
  • Milanov V; University Hospital for Respiratory Diseases "St. Sofia", Sofia, Bulgaria. Electronic address: vlmilanov@yahoo.com.
  • Falzon D; Global TB Programme, World Health Organization, Geneva, Switzerland.
  • Zamfirova M; Public Health Directorate, Ministry of Health, Sofia, Bulgaria.
  • Varleva T; Public Health Directorate, Ministry of Health, Sofia, Bulgaria.
  • Bachiyska E; National Tuberculosis Reference Laboratory (NRL-TB), National Centre of Infectious and Parasitic Diseases (NCIPD), Sofia, Bulgaria.
  • Koleva A; Specialized Hospital for Active Treatment of Lung Diseases, Gabrovo, Bulgaria.
  • Dara M; World Health Organization Regional Office for Europe, Copenhagen, Denmark.
Int J Mycobacteriol ; 4(2): 131-7, 2015 Jun.
Article em En | MEDLINE | ID: mdl-26972881
ABSTRACT

OBJECTIVE:

To analyze determinants of success and death in multidrug-resistant tuberculosis patients (MDR-TB; resistance to, at least, isoniazid and rifampicin) placed on treatment in Bulgaria during the period September 2009 to March 2010 using logistic regression.

RESULTS:

Fifty MDR-TB patients started treatment. MaleFemale ratio was 2.31; mean age 43 years (range 18-77); 19 patients (38%) were new; median duration of disease before treatment was 5 years (range 1-13). All patients tested negative for HIV. Eight cases had XDR-TB (MDR-TB plus resistance to any fluoroquinolone and any second-line injectable). Twenty-four months after starting treatment, 24 patients (48%) had a successful outcome, in 6 (12%) treatment failed, 19 (38%) died, and one (2%) interrupted treatment. XDR-TB cases experienced higher mortality than others (75% vs. 30.9%, respectively, P<0.05). Sputum smear positivity at start of treatment and weight loss or no weight gain were positively associated with death (adjusted Odds ratio 5.16; 95% confidence interval 1.16-22.84 and 5.61; 1.48-21.20, respectively) and negatively with success (0.13; 0.02-0.94 and 0.02; 0.00-0.19). No previous TB treatment increased likelihood of success (7.82; 1.09-56.15). DISCUSSION AND

CONCLUSIONS:

Most MDR-TB patients in this first treatment cohort using WHO-recommended norms had advanced disease explaining the high mortality and low success. Early, adequate treatment of MDR-TB patients can improve outcomes and avert transmission.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose Resistente a Múltiplos Medicamentos / Antituberculosos Tipo de estudo: Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Int J Mycobacteriol Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose Resistente a Múltiplos Medicamentos / Antituberculosos Tipo de estudo: Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Int J Mycobacteriol Ano de publicação: 2015 Tipo de documento: Article